GILD Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $2.3M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| O'Day Daniel Patrick 3 fills | Chairman & CEO | Sell 10b5-1 | 15,000 | $148.64 | $2.2M | 590,533 −2.5% of holding | |
| WELTERS ANTHONY 4 fills | Director | Sell 10b5-1 | 18,000 | $148.62 | $2.7M | 19,774 −47.7% of holding | |
| Bluestone Jeffrey 5 fills | Director | Sell 10b5-1 | 5,000 | $145.02 | $725.1K | 10,066 −33.2% of holding | |
| Mercier Johanna 2 fills | Chief Comm & Corp Aff Officer | Sell 10b5-1 | 28,000 | $137.64 | $3.9M | 129,704 −17.8% of holding | |
| Dickinson Andrew D | Chief Financial Officer | Sell 10b5-1 | 3,000 | $138.36 | $415.1K | 165,646 −1.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.